An interventional study of Nutritious Shake and Nutritional counseling in Chronic Kidney Diseases and Protein-Energy Malnutrition, sponsored by NIN Institute. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by NIN Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Renal Insufficiency, Chronic with a site in Mexico — 19 open to participants now, 31 under way, 14 of them phase 3. Renal Insufficiency, Chronic · Mexico.
Among the 83 studies in Renal Insufficiency, Chronic with a site in Mexico, this one is the 65th largest by planned enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2018, is one of 17 with no phase, reaches primary completion later than 1 of the 30 other live ones, and was the 63rd registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →19 of the 83 studies in Renal Insufficiency, Chronic with a site in Mexico are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Mexico, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Mexico, United States, Argentina and 34 more countries
Ages 18+
Universidad Autonoma de Nuevo Leon · Sites in Mexico
Ages 18+
Centenario Hospital Miguel Hidalgo · Sites in Mexico
Ages 14–18
Eli Lilly and Company · Sites in Mexico, Argentina, Australia and 35 more countries
Ages 50+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 46 · Phase 4 3
First in 2003; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 341 across the 77 interventional studies, 2,807 across the 6 observational. Of the 47 that completed or were terminated, 33 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
NIN Institute is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
NIN Institute has 2 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
10 of the studies in Renal Insufficiency, Chronic with a site in Mexico that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07678203Hospital Civil Juan I. MenchacaDapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis | 2027-01-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 83 studies in Renal Insufficiency, Chronic with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients whit chronic kidney disease (CKD) there is a high prevalence of nutritional disorders and negative changes in body composition, which is strongly associated with an increased risk of morbidity and mortality.
Epidemiological studies have reported that between 30 and 50% of patients with kidney disease show signs of malnutrition and that specifically in patient with CKD in stages 4-5 without replacement therapy, the prevalence of protein energy wasting (PEW) can be up to 45%.
Many factors influence the development of PEW, however, one main factor is insufficient intake of energy and macronutrients. The main obstacle that prevents the patient from meeting their nutritional requirements is the presence of gastrointestinal symptoms. In addition to this, dietary restrictions, lack of adherence to eating plans and the presence of digestive and psychological abnormalities of the patient, contribute directly to the patient directly contribute to insufficient energy and protein intake. Therefore, there is a need for evidence-based nutritional treatment strategies that facilitate the patient's achievement of their nutritional requirements and maintain or improve their nutritional supplements in patients with CKD has been shown to be a good treatment strategy.
Specifically in patients with CKD without replacement therapy, it has been observed that the use of specialized nutritional supplements can contribute to increasing their energy, fat, and fiber intake, while at the same time achieving a decrease in protein intake without causing any change in serum minerals or electrolytes.
This project will provide practical information for the validation of the therapeutic effect of a new specialized food supplement on the nutritional status and quality of life in patients with CKD without replacement therapy, which will be useful both for health professionals and for the patients themselves.
MAIN OBJETIVE:
To assess the effect and safety of the use of a specialized food supplement on the nutritional status and quality of life of patients with CKD and PEW without replacement therapy.
STUDIO DESING:
Randomized, blinded clinical trial with an intervention period of 4 months.
PROCESS:
Pre - Nutritional wash out appointment - nutritionist
0 - Full Assessment Nutritional Appointment - Nutritionist
Perform an evaluation of nutritional status, quality of life and body composition.
Offer nutritional treatment according to the assigned intervention group.
month 1 - Nutritional monitoring appointment - nutritionist
month 2 - Full Assessment Nutritional Appointment - Nutritionist
month 3 - Nutritional monitoring appointment - nutritionist
5.Evaluate adherence to the eating plan. 6.Offer nutritional treatment according to the assigned intervention group. 7.Schedule in 30 days for your next nutritional appointment. 7.1Schedule a few days before your nutritional appointment for blood and urine lab tests.
month 4 - Full Assessment Nutritional Appointment - Nutritionist
SAMPLE SIZE: 50 participants
STATISTIC ANALYSIS:
For the comparison of proportions between the groups, it will be done with X2 or Fisher's exact test and to compare quantitative variables, Student's T or Mann-Whitney U will be used. For the intra-group comparisons, Mc Nemar will be used for the qualitative variables and Anova for repeated samples or Friedman's Anova for the quantitative variables. For the analysis of the interaction or intervening variables, a stratified statistical analysis will be carried out, using contingency tables and the Mantel-Haenszel method. The results will be considered statistically significant if the value of p \<0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Elimination Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention group: The specialized oral supplement is provided, with the consumption of 1 serving (70g-dissolved in 237 ml natural water) per day in conjunction with individualized nutritional counseling. For 4 months
Dietary Supplement: Nutritious Shake
Control group: They receive specialized nutrition considering the recommendations of the clinical practice guidelines for CKD. For 4 months
Behavioral: Nutritional counseling
Powder 70 g/d diluted in 237 ml natural water
Also known as: NIN
Specialized nutritional recommendations for CKD
Serum Albumin (g/dl)
Changes in serum albumin (g/dl) for all the patients at baseline and month 4.
Time frame: baseline intervention and 4 months
Dietary intake (kcal/kg/day)
Changes in dietary caloric intake of patients at baseline and month 4.
Time frame: baseline intervention and 4 months
Adherence to nutritional treatment
Number of patients who manage to adhere correctly to the treatment, applying a Likert scale.
Time frame: baseline intervention and 4 months
Adverse effects
Number of patients who present adverse effects during the intervention, considering frequency and intensity by applying SAS (symptom assessment scale) and Bristol Scale.
Time frame: baseline intervention and 4 months
Plan to share: No
Started Jul 2018 (actual). Primary completion is estimated for Feb 2025, 79 months after the start.
Of 40 industry-sponsored interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 79 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
NIN Institute